Misplaced Pages

Mavacoxib

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Veterinary drug

Pharmaceutical compound
Mavacoxib
Clinical data
Trade namesTrocoxil
AHFS/Drugs.comInternational Drug Names
ATCvet code
Legal status
Legal status
  • EU: Rx-only
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
CompTox Dashboard (EPA)
ECHA InfoCard100.248.948 Edit this at Wikidata
Chemical and physical data
FormulaC16H11F4N3O2S
Molar mass385.34 g·mol
3D model (JSmol)
SMILES
  • C1=CC(=CC=C1C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F)F
InChI
  • InChI=1S/C16H11F4N3O2S/c17-11-3-1-10(2-4-11)14-9-15(16(18,19)20)22-23(14)12-5-7-13(8-6-12)26(21,24)25/h1-9H,(H2,21,24,25)
  • Key:TTZNQDOUNXBMJV-UHFFFAOYSA-N

Mavacoxib (trade name Trocoxil) is a veterinary drug used to treat pain and inflammation in dogs with degenerative joint disease. It acts as a COX-2 inhibitor.

Mavacoxib, along with several other COX-2 selective inhibitors, including celecoxib, valdecoxib, and parecoxib, were discovered by a team at the Searle division of Monsanto led by John Talley.

References

  1. "Trocoxil EPAR". European Medicines Agency. 22 September 2008. Retrieved 26 June 2024.
  2. European Public Assessment Report (EPAR): Trocoxil Archived 17 March 2018 at the Wayback Machine, European Medicines Agency
  3. Cox SR, Lesman SP, Boucher JF, Krautmann MJ, Hummel BD, Savides M, et al. (October 2010). "The pharmacokinetics of mavacoxib, a long-acting COX-2 inhibitor, in young adult laboratory dogs". Journal of Veterinary Pharmacology and Therapeutics. 33 (5): 461–70. doi:10.1111/j.1365-2885.2010.01165.x. PMID 20840390.{{cite journal}}: CS1 maint: overridden setting (link)
  4. Langreth R (23 June 2003). "The Chemical Cobbler". Forbes.{{cite news}}: CS1 maint: overridden setting (link)
  5. "Dr. John Talley: 2001 St. Louis Awardee" (PDF). Chemical Bond. 52 (5). St. Louis Section, American Chemical Society: 2. May 2001. Archived from the original (PDF) on 15 April 2018.
Non-steroidal anti-inflammatory drugs (NSAIDs) (primarily M01A and M02A, also N02BA)
pyrazolones /
pyrazolidines
salicylates
acetic acid derivatives
and related substances
oxicams
propionic acid
derivatives (profens)
n-arylanthranilic
acids (fenamates)
COX-2 inhibitors
(coxibs)
other
NSAID
combinations
Key: underline indicates initially developed first-in-class compound of specific group; WHO-Essential Medicines; withdrawn drugs; veterinary use.
Prostanoid signaling modulators
Receptor
(ligands)
DP (D2)Tooltip Prostaglandin D2 receptor
DP1Tooltip Prostaglandin D2 receptor 1
DP2Tooltip Prostaglandin D2 receptor 2
EP (E2)Tooltip Prostaglandin E2 receptor
EP1Tooltip Prostaglandin EP1 receptor
EP2Tooltip Prostaglandin EP2 receptor
EP3Tooltip Prostaglandin EP3 receptor
EP4Tooltip Prostaglandin EP4 receptor
Unsorted
FP (F2α)Tooltip Prostaglandin F receptor
IP (I2)Tooltip Prostacyclin receptor
TP (TXA2)Tooltip Thromboxane receptor
Unsorted
Enzyme
(inhibitors)
COX
(PTGS)
PGD2STooltip Prostaglandin D synthase
PGESTooltip Prostaglandin E synthaseHQL-79
PGFSTooltip Prostaglandin F synthaseBimatoprost
PGI2STooltip Prostacyclin synthaseTranylcypromine
TXASTooltip Thromboxane A synthase
Others
See also
Receptor/signaling modulators
Leukotriene signaling modulators
Portal:


Stub icon

This veterinary medicine–related article is a stub. You can help Misplaced Pages by expanding it.

Stub icon

This drug article relating to the musculoskeletal system is a stub. You can help Misplaced Pages by expanding it.

Categories:
Mavacoxib Add topic